Pulse 탐색 nav.journalClub 토론 트렌드 연구자 저널

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

홈 탐색 nav.journalClub 트렌드

⌘+K

April 9, 2024

View Full Paper

BHV-2100, a First-in-class TRPM3 Antagonist for the Treatment of Pain (S13.002)

JVJoris VriensEndometriosis JVJean‐Christophe VanherckKU Leuven AMArnaud MarchandKU Leuven

Key Points

Key points are not available for this paper at this time.

Abstract

Assess in vitro activity and in vivo efficacy and safety of BHV-2100.

AI에게 질문

Like

Bookmark

Share

View Full Paper

AI에게 질문

Like

Bookmark

Share

View Full Paper

Cite This Study

Vriens et al. (Tue,) studied this question.

synapsesocial.com/papers/68e6fdb8b6db64358767840d https://doi.org/https://doi.org/10.1212/wnl.0000000000206209

BHV-2100, a First-in-class TRPM3 Antagonist for the Treatment of Pain (S13.002) | Synapse

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1KHN702, a Novel Selective hNav1.8 Inhibitor for Pain Therapy (S38.002)2026
2Phase 1 Study Evaluating the Safety and Tolerability of BHV-7000, a Novel, Selective Kv7.2/7.3 Potassium Channel Activator, in Healthy Adults (P8-1.007)2024 · 8 citations
3Characterization of BHV-7000: A Novel Kv7.2/7.3 Activator for the Treatment of Seizures (S29.006)2024 · 2 citations
4Inhibition of transient receptor potential vanilloid 1 (TRPV1) by a novel selective antagonist for anti-nociceptive effect on inflammatory pain without hyperthermia2026
5Subcutaneous administration of a novel TRPM8 antagonist reverses cold hypersensitivity while attenuating the drop in core body temperature2024 · 9 citations